RNA-seq analysis identified hormone-related genes associated with prognosis of triple negative breast cancer

Triple negative breast cancer(TNBC) is an aggressive subtype of breast cancer that currently lacks effective biomarkers and therapeutic targets required to investigate the diagnosis and treatment of TNBC. Here we performed a comprehensive differential analysis of 165 TNBC samples by integrating RNA-seq data of breast tumor tissues and adjacent normal tissues from both our cohort and The Cancer Genome Atlas(TCGA). Pathway enrichment analysis was conducted to evaluate the biological function of TNBC-specific expressed genes. Further multivariate Cox proportional hazard regression was performed to evaluate the effect of these genes on TNBC prognosis. In this report, we identified a total of 148 TNBC-specific expressed genes that were primarily enriched in mammary gland morphogenesis and hormone levels related pathways, suggesting that mammary gland morphogenesis might play a unique role in TNBC patients differing from other breast cancer types. Further survival analysis revealed that nine genes(FSIP1, ADCY5, FSD1, HMSD, CMTM5, AFF3, CYP2 A7, ATP1 A2,and C11 orf86) were significantly associated with the prognosis of TNBC patients, while three of them(ADCY5,CYP2 A7, and ATP1 A2) were involved in the hormone-related pathways. These findings indicated the vital role of the hormone-related genes in TNBC tumorigenesis and may provide some independent prognostic markers as well as novel therapeutic targets for TNBC.

Expression of MxA Protein in Triple Negative Breast Cancer and its Relationship with Prognosis

Objective:To explore the expression of human myxovirus resistance protein A(MxA)in triple negative breast cancer(TNBC)and its relationship with prognosis.Methods:144 cases of TNBC confirmed by pathology before or after surgery from January 2014 to January 2017 in the First Central Hospital of Baoding City were retrospectively collected.Western blotting was used to detect the expression of MxA protein in TNBC and adjacent breast tissues.According to the expression of MxA protein,144 TNBC patients were divided into low MxA protein expression group(n=91)and MxA protein high expression group(n=53)for subsequent comparison of prognosis of patients in between these two groups.Results:The expression of MxA protein in TNBC tissue was lower than that of adjacent breast tissue,and the difference was statistically significant(P<0.05).The patients in high MxA expression group had higher loco-regional recurrence-free rate,disease-free survival(DFS)rate,and overall survival(OS)rate than those in low MxA expression group for 3 years.On the other hand,the distant metastasis rate was lower in the high expression group compared to that in the low MxA expression group,and the difference was statistically significant(P<0.05).Conclusion:In triple-negative breast cancer,high MxA expression is a potential predictor of TNBC prognosis.

Clinicopathological Characters of Triple Negative Breast Cancer

Objective： To study the clinicopathological characters Methods： A total of 629 patients with breast cancer of triple negative breast cancer （TNBC）. were reviewed, who were treated from 2003 to 2007 in Chongqing Cancer Institute. The comparison of clinicopathological features including TNM classification, histological type, tumor location, axillary lymphonodes status and neoadjuvant chemotherapy between TNBC and nontriple negative breast cancer （NTNBC） was performed. The overall response was evaluated by whether the patients achieve complete remission （CR） and partial remission （PR） after chemotherapy. Results： There were 69 TNBCs in the 629 patients with breast cancer. The premenopausal patients, which was found in 49/69 of TNBCs, was more than NTNBCs. The average diameter of tumor in TNBC group was 4.1 cm, lager than NTNBC group. TNBC with axillary nodes metastasis occurred in 21 cases, and the axillary nodes metastasis rate was lower than NTNBC. The positive expression rate of p53 in TNBC was 44.9%, and the overall response （CR＋PR） was 72.2%. No statistical differences were found regarding the positive expression rate of p53 and the overall response between TNBC and NTNBC. Conclusion： TNBC were a group of primary breast cancers with triple negative, tending to occur in premenopausal women, with larger tumors, lower axillary nodes metastasis rate. TNBC had worse clinical prognosis and currently lacked effective targeted therapies.

Clinical characteristics and prognosis of triple-negative breast cancer

客观我们调查了临床的特征，和三元组否定的乳癌的预示的因素。130 个三元组否定的乳癌病人在临床的特征和预后上被考察的方法。所有情况是免疫组织化学决定的雌激素受体，孕酮受体，和 HER2/neu 的表示的缺乏。结果 17.1% 所有乳癌病人(774 个案例) 是三元组否定的乳癌，并且 68.9% 三元组否定的乳癌病人(91 个案例) 是绝经前的。53.8% 病人(71 个案例) 与 T2 尺寸有肿瘤，并且(52 个病人) 他们中的 39.4% 个有淋巴节点转移。没有淋巴节点转移，在有淋巴节点转移的病人的恶化的率在病人显然比那高(P = 0.001 ) 。后续的中部的时间是 63 个月。33 案例 relapsed 和 20 个病人死了。23 个病人有至少二机关转移。5 年的没有疾病、全面的幸存率是 73.8% 和 85.7% 。结论三元组否定的乳癌病人通常在治疗以后在 2 3 年里有多重远转移的高率。淋巴节点的地位是最重要的预示的因素。有淋巴节点转移的三元组否定的胸 caner 病人有差的预后。

Analysis of the Clinicopathologic Features and Prognosis in Triple-Negative Breast Cancer

OBJECTIVE To investigate the clinical and pathological features,as well as prognosis in triple-negative breast cancer patients.METHODS A total of 509 cases of operable breast cancer from January,2002 to June,2002 treated in the Cancer Hospital of Tianjin Medical University were analyzed.The Her-2,ER and PR status was determined using immunohistochemistry.Of the total cases,one group was identifi ed as triple negative breast cancer,ie defi ned as ER,PR and Her-2 negative.The other group was non-triple-negative breast cancer.Clinicopathologic features of the groups were compared and 5-year disease-free survival(DFS) analyzed by the Kaplan-Meier method.RESULTS Of the total cases,21.4%(109/509) of cases were found to be triple-negative while 78.6%(400/509) were non-triple-negative.The triple negative group had higher incidence rates than the non-triple-negative group of the medullary type and Grade Ⅲ tumors(P < 0.05).There was no other difference in the clinicopathologic features between the 2 groups.From follow-up to June,2007,21.1%(23/109) of the triple-negative group and 12.7%(51/400) of the non-triple negative group had a local recurrence or distant metastasis,resulting in a signifi cant difference(P < 0.05).In the triple-negative group and non-triple-negative group,5-year DFS were 78.9% and 87.3% respectively.There was a statistically signifi cant difference between the 2 groups(P = 0.031).CONCLUSION Compared with non-triple-negative breast cancer,triple-negative breast cancer patients have an increased likehood of a local recurrence or distant metastasis and a poorer prognosis.

Triple negative breast cancer: special histological types and emerging therapeutic methods

Triple negative breast cancer(TN BC)is a complex and malignant breast cancer subtype that lacks expression of the estrogen receptor(ER),progesterone receptor(PR)and human epidermal growth factor receptor 2(H ER2),thereby making therapeutic targeting difficult.TNBC is generally considered to have high malignancy and poor prognosis.However,patients diagnosed with certain rare histomorphologic subtypes of TNBC have better prognosis than those diagnosed with typical triple negative breast cancer.In addition,with the discovery and development of novel treatment targets such as the androgen receptor(AR),PI3K/AKT/mTOR and AMPK signaling pathways,as well as emerging immunotherapies,the therapeutic options for TNBC are increasing.In this paper,we review the literature on various histological types of TNBC and focus on newly developed therapeutic strategies that target and potentially affect molecular pathways or emerging oncogenes,thus providing a basis for future tailored therapies focused on the mutational aspects of TNBC.

Clinicopathological analysis of early-stage breast cancer patients that meet indications for BRCA 1/2 genetic testing

Objective:To investigate the clinicopathological characteristics and prognostic factors of early-stage breast cancer patients with indications for breast cancer susceptibility genes 1/2(BRCA1/2)genetic testing in China.Methods:Based on the indication criteria for BRCA genetic testing specified in the National Comprehensive Cancer Network(NCCN)clinical practice guidelines in oncology,genetic/familial high-risk assessment:Breast and ovarian(Version 2.2019),a retrospective analysis was performed on patients with early-stage invasive breast cancer treated at Breast Disease Center,Peking University First Hospital between January 2008 and December 2016.Clinicopathological characteristics of all patients were analyzed,and prognoses were calculated using the KaplanMeier method and a Cox proportionate hazards model.Results:A total of 906 early-stage breast cancer patients who had indications for BRCA genetic testing and had complete clinicopathological data and follow-up information were included in the study group,accounting for34.7%of all breast cancer patients treated in Breast Disease Center,Peking University First Hospital during the study period.Compared with breast cancer patients without indications for BRCA genetic testing,the overall survival(OS)and disease-free survival(DFS)of patients with indications were not significantly different.In the study group,patients with premenopausal status,high T stage,lymph node positive,estrogen receptor(ER)negative,Ki-67>20%and presence of a vascular tumor thrombus had worse prognosis.There were more family histories of gastrointestinal cancer in patients with related indications than in patients without such indications.Conclusions:Single-center data showed that more than 30%of patients with early-stage breast cancer had indications for BRCA genetic testing.There was no prognostic difference in patients with or without indications for BRCA genetic testing.Premenopausal status,high T stage,lymph node positive,ER negative,Ki-67>20%,and presence of a vascular tumor thrombus were associated with poor prognosis.

基线血清VEGF水平对非三阴性乳腺癌患者临床因素、病理特征及预后的影响

目的分析基线血清血管内皮生长因子(VEGF)水平对非三阴性乳腺癌患者临床因素、病理特征及预后的影响。方法选取2019年1月至2020年12月该院收治的非三阴性乳腺癌患者120例作为研究对象,根据肿瘤TNM分期,将研究对象分别分为TNM分期Ⅰ、Ⅱ期乳腺癌患者80例(A组)和TNM分期Ⅲ期乳腺癌患者40例(B组),比较两组患者血清VEGF水平、临床因素和病理特征。采用受试者工作特征(ROC)曲线分析血清VEGF水平预测乳腺癌Ⅲ期的最佳截断值,采用Kaplan-Meier法绘制总生存率、无病生存率的生存曲线,比较采用Log-rank检验。基线血清VEGF水平对非三阴性乳腺癌总生存率及无病生存率的影响采用多因素Cox回归模型。结果B组血清VEGF、D-二聚体、纤维蛋白原(FIB)、纤维蛋白降解产物(FDP)、癌抗原125(CA-125)和癌抗原15-3(CA15-3)与A组比较,差异有统计学意义(P<0.05)。ROC曲线分析结果显示,非三阴性乳腺癌TNM分期Ⅲ期的血清VEGF的曲线下面积为0.875,95%CI(0.802~0.948),P<0.001。血清VEGF≥180.40 pg/mL患者的D-二聚体、FIB、FDP水平、CA-125、CA15-3水平高于血清VEGF<180.40 pg/mL患者,差异有统计学意义(P<0.05)。血清VEGF<180.40 pg/mL患者肿瘤T1分期、肿瘤N0、N1分期、TNM分期Ⅰ/Ⅱ期、Luminal A型占比高于血清VEGF≥180.40 pg/mL患者,差异有统计学意义(P<0.05)。血清VEGF<180.40 pg/mL患者的无病生存率明显高于血清VEGF≥180.40 pg/mL患者,差异有统计学意义(P<0.001)。矫正各项指标后,VEGF≥180.40 pg/mL为非三阴性乳腺癌复发转移的危险因素[HR=2.563,95%CI(1.772~3.708),P<0.001]。结论高基线VEGF水平与非三阴性乳腺癌进展有关,是其预后的影响因素。

FGFR1蛋白在ER阳性乳腺癌中的表达情况及其与ER、预后的相关性

目的探讨成纤维细胞生长因子受体1(FGFR1)蛋白在雌激素受体(ER)阳性乳腺癌中的表达水平及与ER、预后的关系。方法回顾性分析89例ER阳性乳腺癌患者临床资料。所有患者均行手术治疗,术后及时送检肿瘤标本,经免疫组织化学法检测FGFR1蛋白表达情况。统计FGFR1蛋白表达在ER阳性乳腺癌中的表达水平,分析不同FGFR1表达患者临床病理特征差异;比较不同FGFR1蛋白表达患者生存率差异。结果89例ER阳性乳腺癌患者体内均存在FGFR1蛋白表达,其中高表达58例,低表达31例;高、低表达组肿瘤分期、肿瘤大小、淋巴结转移、ER表达相比,差异有统计学意义(P<0.05)。随访3年,89例ER阳性患者存活71例,存活率为79.78(71/89);FGFR1蛋白低表达组存活率为93.55%(29/31),高于FGFR1蛋白高表达组72.41%(42/58),差异有统计学意义(χ^(2)=5.593,P=0.018)。结论FGFR1蛋白在ER阳性乳腺癌中存在不同程度表达,且FGFR1蛋白高表达患者ER表达水平偏低,并可对患者预后造成影响。

PD-L1、miR-29a、miR let-7a对三阴性乳腺癌患者预后的评估价值分析

目的探讨程序性死亡蛋白配体-1(PD-L1)、微小RNA-29a(miR-29a)、微小RNA let-7a(miR let-7a)在三阴性乳腺癌(TNBC)患者预后评估中的临床价值。方法将67例TNBC患者作为观察组,同期收治的67例乳腺良性肿物患者作为对照组。所有患者均采集标本送检,测定PD-L1表达水平,并采集5 ml空腹静脉血,采用实时荧光定量PCR法测定miR-29a、miR let-7a表达情况,分析PD-L1、miR-29a、miR let-7a与其临床病理特征及预后的关系。结果观察组PD-L1阳性率、miR-29a表达量、miR let-7a表达量高于对照组,PD-L1阳性组临床分期Ⅲ期、淋巴结转移率高于PD-L1阴性组,临床分期Ⅲ期、淋巴结转移患者miR-29a、miR let-7a表达水平高于临床分期Ⅰ~Ⅱ期、无淋巴结转移患者,差异有统计学意义(P<0.05);67例患者随访3年后存活率为59.70%(40/67);PD-L1阳性患者存活率低于PD-L1阴性患者,存活者miR-29a、miR let-7a表达水平低于死亡组,差异有统计学意义(P<0.05)。结论PD-L1、miR-29a、miR let-7a在TNBC中呈高表达,与临床分期、淋巴结转移关系密切,且高表达患者存活率更低,可作为临床评估预后的重要指标。

HER-2低表达乳腺癌患者的临床病理特征分析

目的:探讨HER-2低表达乳腺癌患者的临床病理特征,为其独立分型及精准治疗提供临床病理数据支持。方法:收集非特殊型浸润性乳腺癌患者的临床病理资料,把HER-2阴性患者分为HER-2不表达[免疫组化结果HER-2(0)]和HER-2低表达[免疫组化结果HER-2 (1+),或HER-2(2+)且原位杂交结果无扩增(ISH-)]两组对比研究。结果:HER-2低表达乳腺癌患者淋巴结转移率高于HER-2不表达患者(P<0.05),Spearman秩相关分析显示HER-2表达量与淋巴结转移率成正相关(rs=0.210,P<0.05)。结论:HER-2低表达有着不同于HER-2不表达的临床病理特征,其有望独立成为新的分子分型,对其深入研究,有利于改变HER-2低表达乳腺癌患者治疗模式,为其提供更精准的治疗。

乳腺癌组织中FOXP3、CMTM6、Shoc2表达及其临床意义

目的探讨叉头框蛋白P3(FOXP3)、趋化素样因子超家族6(CMTM6)、Shoc2在乳腺癌组织中的表达及与患者临床病理特征、预后的关系。方法选取51例女性乳腺癌患者为研究对象,采集癌组织与癌旁正常组织,以免疫组织化学法测定FOXP3、CMTM6、Shoc2的阳性表达。收集患者的年龄等一般资料,分析FOXP3、CMTM6、Shoc2表达与乳腺癌临床病理特征之间的关系;随访3年,分析三项指标表达与患者预后的关系。结果癌组织FOXP3、CMTM6、Shoc2阳性表达率高于癌旁组织,差异有统计学意义(P<0.05)。FOXP3、CMTM6、Shoc2表达与乳腺癌患者的年龄、体重指数(BMI)、肿瘤大小无关(P>0.05);FOXP3、CMTM6、Shoc2表达与患者的分化程度、临床分期、淋巴结转移有关(P<0.05)。FOXP3、CMTM6、Shoc2阳性表达患者的3年生存率低于阴性表达患者,差异有统计学意义(P<0.05)。结论FOXP3、CMTM6、Shoc2在乳腺癌组织内呈高表达,与患者的分化程度、临床分期、淋巴结转移联系紧密,参与疾病的发生与发展,且三项指标表达水平越高,则患者预后越差。

乳腺癌组织中miR-199b-5p和MTA1表达水平与临床病理特征和预后的关系

目的 检测乳腺癌组织中miR-199b-5p与MTA1表达情况,并分析其表达水平与临床病理特征和预后关系。方法 选取2017年10月至2018年10月期间河南大学第一附属医院收治的行乳腺切除手术的乳腺癌患者135例作为研究对象,取其癌组织与癌旁组织分别作为癌旁组织组与乳腺癌组,qRT-PCR法测定癌组织与癌旁组织miR-199b-5p、MTA1 mRNA水平,免疫组化法分析组织MTA1阴阳性,分析miR-199b-5p、MTA1表达与乳腺癌患者年龄、绝经情况(是、否)、肿瘤直径(<2 cm、≥2 cm)、临床分期(Ⅰ~Ⅱ期、Ⅲ期)、分子分型(Lumina A/B型、HER-2阳性型、三阴性型)、淋巴结转移(是、否)关系。结果 与癌旁组织组相比,乳腺癌组癌组织miR-199b-5p水平降低,MTA1 mRNA水平升高(P<0.05);与癌旁组织组相比,乳腺癌组MTA1阳性率升高(P<0.05);乳腺癌患者癌组织miR-199b-5p表达与临床分期、淋巴结转移有关(P<0.05);MTA1表达与临床分期、淋巴结转移、分子分型有关(P<0.05);乳腺癌患者治疗后进行5年随访,miR-199b-5p低表达患者5年内累积生存率(71.8%)低于miR-199b-5p高表达患者(89.1%)(log Rankχ^(2)=6.661,P=0.010);MTA1阳性患者5年内累积生存率(71.6%)低于MTA1阴性患者(90.2%)(log Rankχ^(2)=7.590,P=0.006);单因素COX分析表明,肿瘤直径、临床分期、分子分型、淋巴结转移、miR-199b-5p、MTA1是影响乳腺癌预后不良的危险因素(P<0.05);多因素COX回归分析显示,临床分期、淋巴结转移、miR-199b-5p、MTA1水平是影响乳腺癌预后的危险因素(P<0.05)。结论 乳腺癌患者miR-199b-5p低表达,MTA1 mRNA与阳性率高于癌旁组织,miR-199b-5p低水平、MTA1阳性表达与乳腺癌患者临床病理特征淋巴结转移、肿瘤分期以及患者预后密切相关,两者可能是乳腺癌患者预后不良的预测靶基因。

SOX10、EGFR检测对于浸润性三阴性乳腺癌的预后价值

目的检测SOX10、EGFR蛋白在浸润性三阴性乳腺癌患者的组织标本中的表达情况,分析其与患者临床病理特征的关系及预后价值。方法回顾性分析2012年1月至2021年10月于我院诊治的80例乳腺癌患者资料,收集所有患者的乳腺癌组织标本,采用免疫组织化学染色法(IHC)检测乳腺癌组织中SOX10、EGFR蛋白表达情况,分析SOX10阳性表达与阴性表达两组患者的EGFR蛋白表达水平差异,并分析SOX10、EGFR与乳腺癌患者临床病理特征的相关性,探讨SOX10、EGFR表达水平对患者总体生存(OS)的影响。通过COX多因素回归分析影响患者OS的独立危险因素。结果不同年龄、肿瘤分化程度的乳腺癌患者组织中SOX10、EGFR阳性表达率差异均无统计学意义(P均>0.05),肿瘤大小≥2cm、TNM分期为II/III期、存在淋巴结转移的患者较肿瘤大小<2cm、TNM分期为I期、无淋巴结转移者SOX10、EGFR阳性表达率更高,差异具有统计学意义(P均<0.05)。SOX10阳性表达组的EGFR表达率为74.4%(29/39),较阴性组24.4%(10/41)的高,差异具有统计学意义(χ^(2)=19.975,P<0.001)。单因素分析结果显示,TNM分期、肿瘤最大径、淋巴结转移状态、SOX10、EGFR的表达水平是影响患者OS的因素(P=0.013、0.027、<0.001、0.015、<0.001),多因素分析结果显示,TNM分期、淋巴结转移状态、SOX10和EGFR的表达是影响患者OS的独立危险因素(P=0.020、0.042、0.037、0.032)。SOX10阳性表达组患者的中位OS为17个月,显著低于阴性表达组的37个月,差异具有统计学意义(HR=2.078,95%CI 1.217~3.543,P=0.004),EGFR阳性表达组患者的中位OS为20.5个月,显著低于阴性表达组的36个月,差异具有统计学意义(HR=1.819,95%CI 1.074~3.083,P=0.019)。结论SOX10和EGFR可能存在共表达关系,且两者的表达情况与乳腺癌的进展密切相关,均可作为患者预后评估的分子标志物。

早期三阴性乳腺癌中雄激素受体表达与临床病理特征及预后的关系

目的 探讨雄激素受体(androgen receptor,AR)在早期三阴性乳腺癌(triple negative breast cancer,TNBC)中的表达与临床病理特征及预后的关系。方法 回顾分析2010年1月至2014年12月在十堰市太和医院甲乳外科收治的185例早期TNBC患者的病例资料,通过免疫组化方式检测AR的表达情况,分析AR表达与临床病理指标之间的关系以及AR对患者预后的影响。结果 185例早期TNBC患者中,AR阳性表达54例(29.2%)。较AR阴性患者,AR阳性患者具有组织学分级低、肿瘤直径小、淋巴结转移率低、p53阳性率低及Ki-67低表达的特征(P <0.05)。AR表达情况与年龄、月经状态、放化疗及脉管癌栓无相关性(P> 0.05)。中位随访63个月,41例发生复发转移(22.2%),死亡27例(14.6%)。AR阳性患者较AR阴性患者具有更好的无病生存期和总生存期(P <0.05),且多因素分析显示AR阳性是患者总生存期独立的影响因素。结论 早期TNBC患者中AR阳性表达与组织学分级低、肿瘤直径小、Ki-67增殖指数低等预后良好临床病理指标存在关联性,且是总生存期独立的保护因素,提示AR可能成为TNBC的治疗靶点和预后指标。

HES3对乳腺癌淋巴转移的影响

目的探讨HES3表达与乳腺癌临床病理特征的相关性。方法收集114例女性乳腺癌患者的临床资料。免疫组织化学染色检测HES3在乳腺癌组织中的表达水平。分析HES3表达水平与临床病理特征的相关性。结果114例样本中,HES3在26例(22.80%)乳腺癌组织中表达。与HES3阴性比较,HES3阳性患者淋巴转移率高(P=0.001),肿瘤较大(P<0.001)。多因素分析显示,肿瘤较大与HES3高表达是乳腺癌淋巴转移的危险因素。结论HES3的高表达与女性乳腺癌患者淋巴转移和肿瘤大小有关,其可作为预测乳腺癌淋巴转移的预后标志物。

双侧原发性乳腺癌腋窝淋巴结转移特点及其与预后的相关性分析

目的 探究双侧原发性乳腺癌临床病理特点,分析腋窝淋巴结转移与临床病理的相关性。方法 回顾性选取2006年1月至2022年3月两家医院收治的96例女性双侧原发性乳腺癌患者临床病理资料,分析患者腋窝淋巴结转移及预后特点。结果 96例双侧原发性乳腺癌患者,第一癌91例为浸润性癌,55例发生腋窝淋巴结转移,转移率60.4%;第二癌81例为浸润性癌,36例发生腋窝淋巴结转移,转移率44.4%;两侧腋窝淋巴结转移差异无统计学意义(P>0.05)。单因素分析发现,第二癌肿块长径越长、组织学分级越高同侧腋窝淋巴结转移率更高(P<0.05);第二癌ER表达阴性较ER阳性表达同侧腋窝淋巴结转移率更高(P<0.05)。单因素生存分析提示,双侧腋窝淋巴结转移组较无转移组及单侧转移组无病生存率低(P<0.05),双侧病灶ER、PR一致阴性患者预后最差,ER、PR一致阳性患者预后最好(P<0.05),双侧pTNM高分期(III期)较双侧低分期及单侧高分期预后更差(P<0.05)。多因素生存分析显示双侧ER阳性是影响BPBC患者无病生率的保护性因素,双侧肿瘤pTNM高分期是其危险因素。结论 双侧原发性乳腺癌两侧癌灶有一定独立性;双侧腋窝淋巴结转移者有更高的局部复发及远处转移风险,预后不良,需密切随访监测。

乳腺癌组织STRAP表达及临床意义

目的探讨丝氨酸-苏氨酸激酶受体相关蛋白(STRAP)在乳腺癌中的表达情况与病理意义、预后关系分析。方法回顾性选取2018-01—2020-03河北中石油中心医院收治的100例乳腺癌患者作为观察组,及2018-01—2020-03乳腺良性病变者70例作为对照组,采用免疫组化染色法检测两组STRAP表达,分析STRAP表达与临床病理的关系、采用回归分析STRAP表达与患者预后的关系。结果观察组STRAP阳性表达率高于对照组,差异有统计学意义(P<0.05);STRAP阳性表达率与病理分期、淋巴结转移、雌激素受体、HER2有关(P<0.05);STRAP表达与ER、HER2表达有相关性(P<0.05)。STRAP阳性表达乳腺癌患者平均无进展生存时间为33个月(95%CI:31.66~34.34),明显短于STRAP阴性表达乳腺癌患者(P<0.05);Cox比例风险回归显示:TNM分期、淋巴结转移、STRAP表达是乳腺癌患者预后的影响因素(HR=2.011、1.722,P<0.05)。结论乳腺癌组织中STRAP表达上调,在疾病发生发展中有一定作用,同时是患者预后的影响因素。

DEPDC1B、NOB1水平变化与三阴性乳腺癌患者相关病理学参数的关系

目的 探讨DEP结构域蛋白质1B(DEPDC1B)、Nin-one结合蛋白(NOB1)水平变化与三阴性乳腺癌(triple negative breast cancer, TNBC)患者相关病理学参数的关系及临床意义。方法 选取行乳腺癌根治术的81例TNBC患者设为观察组,选取同期因乳腺良性疾病行手术治疗的21例患者设为对照组。随访1年后(失访6例)根据预后情况分为预后良好者57例(生存)、预后不良者18例(病死、病情恶化或复发)。比较TNBC组织、癌旁组织、良性病变组织中DEPDC1B、NOB1表达量。分别比较不同病理学参数、不同预后患者癌组织中DEPDC1B、NOB1表达量。分析DEPDC1B、NOB1表达量与病理学参数、预后相关性。结果 TNBC组织、良性病变组织中DEPDC1B、NOB1表达量高于癌旁组织,且TNBC组织高于良性病变组织(P<0.05);预后不良者中DEPDC1B、NOB1表达量高于预后良好者(P<0.05);DEPDC1B、NOB1表达量与淋巴结转移、临床分期、脉管瘤栓呈正相关,与分化程度呈负相关(P<0.05);DEPDC1B、NOB1高表达者总生存率(66.67%、65.79%)分别低于其相应低表达者86.11%、86.49%(P<0.05)。结论 DEPDC1B、NOB1在TNBC组织中呈高表达,且与临床病理学参数相关,可能用于预后评估。

三阴型乳腺癌临床病理特征及预后分析

目的:分析三阴型乳腺癌的临床病理特征及其预后。方法:选取2002年1月～2002年6月天津医科大学附属肿瘤医院收治的可手术乳腺癌509例,进行免疫组织化学法测定Her-2、ER、PR蛋白表达并分为两组,一组为三阴型(Triple-Negative)即Her-2(-),ER(-),PR(-),另一组为非三阴型乳腺癌。比较三阴型和非三阴型乳腺癌的临床病理特征,Kaplan-Meier法分析两组乳腺癌的5年无瘤生存率。结果:21.4%(109/509)的病例为三阴型乳腺癌,其髓样癌、组织学Ⅲ级的比例以及复发转移率高于非三阴型乳腺癌(P<0.05)。三阴型乳腺癌和非三阴型乳腺癌5年无瘤生存率分别为78.9%和87.3%,两组比较差异具有统计学意义(P=0.031)。结论:三阴型乳腺癌比非三阴型乳腺癌易发生局部复发和远处转移,临床预后差。